scholarly journals Practical guidance for echocardiography for cancer therapeutics-related cardiac dysfunction

2020 ◽  
Author(s):  
Tetsuari Onishi ◽  
◽  
Yuko Fukuda ◽  
Sakiko Miyazaki ◽  
Hirotsugu Yamada ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Cancer Treatment ◽  
Cancer Therapeutics ◽  
Medical System ◽  
Clinical Settings ◽  
Patients With Cancer ◽  
Early Diagnosis Of Cancer ◽  
Diagnosis Of Cancer ◽  
Practical Guidance

Abstract The prognosis of patients with cancer has improved due to an early diagnosis of cancer and advances in cancer treatment. There are emerging reports on cardiotoxicity in cancer treatment and on cardiovascular disease in cancer patients, from which cardiovascular disease has been recognized as a common cause of death among cancer survivors. This situation has led to the need for a medical system in which oncologists and cardiologists work together to treat patients. With the growing importance of onco-cardiology, the role of echocardiography in cancer care is rapidly expanding, but at present, the practice of echocardiography in clinical settings varies from institution to institution, and is empirical with no established systematic guidance. In view of these circumstances, we thought that brief guidance for clinical application was necessary and have therefore developed this guidance, although evidence in this field is still insufficient.

Cancer-related fatigue: an overview

2021 ◽  
Vol 30 (4) ◽  
pp. S36-S43
Author(s):  
Mohammed Al Maqbali
Keyword(s):  
Negative Impact ◽  
Management Strategies ◽  
Background Information ◽  
Clinical Settings ◽  
Measurement Scales ◽  
Major Life ◽  
Patients With Cancer ◽  
Cancer Related Fatigue ◽  
Diagnosis Of Cancer ◽  
Life Stressor

A diagnosis of cancer is a major life stressor that can affect the physiological, psychological and physical state of the person concerned. Fatigue is a particularly common and troubling symptom that has a negative impact on quality of life throughout all phases of treatment and stages of the illness. The aim of this review is to provide background information on cancer-related fatigue. This review discusses cancer-related fatigue (CRF) in terms of the definition, prevalence, risk factors, aetiology, and the measurement scales used. The differences between definitions of symptoms and relevant theories will be explored and discussed to help explain the variety of instruments used in its measurement. The prevalence of fatigue will be assessed by looking critically at the evidence of fatigue and the factors that affect it. Potential treatment and management strategies for CRF will also be discussed. Finally, there will be an overview of the instruments used to measure fatigue. This review also provides important evidence for measuring and managing CRF that can help nurses to understand fatigue among patients with cancer. Assessing CRF should be routinely undertaken in clinical settings to help identify the proper interventions, treatments and management to reduce fatigue among cancer patients.

Innovatory role of nanomaterials as bio-tools for treatment of cancer

2020 ◽  
Vol 0 (0) ◽  
Author(s):  
Khuram Shahzad Ahmad ◽  
Muntaha Talat ◽  
Shaan Bibi Jaffri ◽  
Neelofer Shaheen
Keyword(s):  
Cancer Treatment ◽  
Cancer Therapeutics ◽  
Physicochemical Characteristics ◽  
Global Scale ◽  
Current Review ◽  
Anti Cancer ◽  
Different Types ◽  
Cancerous Cells

AbstractConventional treatment modes like chemotherapy, thermal and radiations aimed at cancerous cells eradication are marked by destruction pointing the employment of nanomaterials as sustainable and auspicious materials for saving human lives. Cancer has been deemed as the second leading cause of death on a global scale. Nanomaterials employment in cancer treatment is based on the utilization of their inherent physicochemical characteristics in addition to their modification for using as nano-carriers and nano-vehicles eluted with anti-cancer drugs. Current work has reviewed the significant role of different types of nanomaterials in cancer therapeutics and diagnostics in a systematic way. Compilation of review has been done by analyzing voluminous investigations employing ERIC, MEDLINE, NHS Evidence and Web of Science databases. Search engines used were Google scholar, Jstore and PubMed. Current review is suggestive of the remarkable performance of nanomaterials making them candidates for cancer treatment for substitution of destructive treatment modes through investigation of their physicochemical characteristics, utilization outputs and long term impacts in patients.

scholarly journals Circulating Autoantibodies to LGALS3BP: A Novel Biomarker for Cancer

2013 ◽  
Vol 35 ◽  
pp. 747-752 ◽  
Author(s):  
Antonino Grassadonia ◽  
Nicola Tinari ◽  
Clara Natoli ◽  
Galit Yahalom ◽  
Stefano Iacobelli
Keyword(s):  
Healthy Subjects ◽  
Malignant Tumors ◽  
Enzyme Linked Immunosorbent Assay ◽  
Age And Gender ◽  
Patients With Cancer ◽  
Early Diagnosis Of Cancer ◽  
Diagnosis Of Cancer ◽  
And Gender ◽  
Circulating Autoantibodies ◽  
Circulating Levels

Purpose. Circulating autoantibodies have been extensively investigated as possible markers for early diagnosis of cancer. The present study was carried out to investigate whether anti-LGALS3BP IgG autoantibodies could be classified as a biomarker for malignant tumors.Methods. An in-house developed enzyme-linked immunosorbent assay was used to detect autoantibodies to LGALS3BP in sera from 71 patients with various types of cancers and 54 healthy subjects matched by age and gender.Results. Patients with cancer have significant higher circulating levels of anti-LGALS3BP antibodies as compared to control subjects (). The test has a sensitivity of 33% and a specificity of 98%.Conclusions. Anti-LGALS3BP IgG autoantibodies are a promising biomarker for malignant tumors and could play a role in the development of a multimarker assay for the early detection of cancer.

scholarly journals The Multifaceted Functions of CXCL10 in Cardiovascular Disease

2014 ◽  
Vol 2014 ◽  
pp. 1-11 ◽  
Author(s):  
Pleunie van den Borne ◽  
Paul H. A. Quax ◽  
Imo E. Hoefer ◽  
Gerard Pasterkamp
Keyword(s):  
Cardiovascular Disease ◽  
Inflammatory Responses ◽  
Clinical Settings ◽  
Key Features ◽  
Tissue Cells ◽  
Inducible Protein ◽  
Chemokine Family ◽  
Interferon Inducible Protein ◽  
Biological Actions

C-X-C motif ligand 10 (CXCL10), or interferon-inducible protein-10, is a small chemokine belonging to the CXC chemokine family. Its members are responsible for leukocyte trafficking and act on tissue cells, like endothelial and vascular smooth muscle cells. CXCL10 is secreted by leukocytes and tissue cells and functions as a chemoattractant, mainly for lymphocytes. After binding to its receptor CXCR3, CXCL10 evokes a range of inflammatory responses: key features in cardiovascular disease (CVD). The role of CXCL10 in CVD has been extensively described, for example for atherosclerosis, aneurysm formation, and myocardial infarction. However, there seems to be a discrepancy between experimental and clinical settings. This discrepancy occurs from differences in biological actions between species (e.g. mice and human), which is dependent on CXCL10 signaling via different CXCR3 isoforms or CXCR3-independent signaling. This makes translation from experimental to clinical settings challenging. Furthermore, the overall consensus on the actions of CXCL10 in specific CVD models is not yet reached. The purpose of this review is to describe the functions of CXCL10 in different CVDs in both experimental and clinical settings and to highlight and discuss the possible discrepancies and translational difficulties. Furthermore, CXCL10 as a possible biomarker in CVD will be discussed.

Cancer treatment and causation

Clinical Risk ◽  
2007 ◽  
Vol 13 (4) ◽  
pp. 151-153
Author(s):  
Victor Barley
Keyword(s):  
Cancer Treatment ◽  
Histological Examination ◽  
Multidisciplinary Team ◽  
Basic Knowledge ◽  
Delay In Diagnosis ◽  
Patients With Cancer ◽  
Cancer Services ◽  
Diagnosis Of Cancer ◽  
The Uk ◽  
Medicolegal Issues

A series of three articles exploring medicolegal issues arising out of the detection and treatment of cancer. The treatment of cancer involves several different specialists and, in the majority of cancer services in the UK, patients with cancer are seen by a multidisciplinary team. After the diagnosis of cancer has been confirmed by histological examination which shows the type and grade of the cancer, further tests are usually needed to determine the extent and spread of the tumour, i.e. the stage. Many cancers have already spread before the diagnosis can be made, even if the metastases cannot be detected at the time of the initial diagnosis. Many cancers are therefore not curable even though there is no indication of spread from the initial tests. Therefore, an unwarranted delay in diagnosis may not result in a poorer prognosis, although it is clearly important to give treatment at the earliest opportunity to reduce the possibility of spread. This article outlines the basic knowledge required by a clinical negligence practitioner when considering a potential oncology claim.

scholarly journals microRNA-23a in Human Cancer: Its Roles, Mechanisms and Therapeutic Relevance

Cancers ◽  
2018 ◽  
Vol 11 (1) ◽  
pp. 7 ◽  
Author(s):  
Ning Wang ◽  
Hor-Yue Tan ◽  
Yi-Gang Feng ◽  
Cheng Zhang ◽  
Feiyu Chen ◽  
...  
Keyword(s):  
Human Cancer ◽  
Migration And Invasion ◽  
Cancer Tissue ◽  
Specific Marker ◽  
Tumor Treatment ◽  
Multiple Gene ◽  
Early Diagnosis Of Cancer ◽  
Different Types ◽  
Diagnosis Of Cancer

microRNA-23a (miR-23a) is one of the most extensively studied miRNAs in different types of human cancer, and plays various roles in the initiation, progression, and treatment of tumors. Here, we comprehensively summarize and discuss the recent findings about the role of miR-23a in cancer. The differential expression of tissue miR-23a was reported, potentially indicating cancer stages, angiogenesis, and metastasis. miR-23a in human biofluid, such as plasma and salivary fluid, may be a sensitive and specific marker for early diagnosis of cancer. Tissue and circulating miR-23a serves as a prognostic factor for cancer patient survival, as well as a predictive factor for response to anti-tumor treatment. The direct and indirect regulation of miR-23a on multiple gene expression and signaling transduction mediates carcinogenesis, tumor proliferation, survival, cell migration and invasion, as well as the response to anti-tumor treatment. Tumor cell-derived miR-23a regulates the microenvironment of human cancer through manipulating both immune function and tumor vascular development. Several transcriptional and epigenetic factors may contribute to the dysregulation of miR-23a in cancer. This evidence highlights the essential role of miR-23a in the application of cancer diagnosis, prognosis, and treatment.

scholarly journals Cellular and Extracellular Components in Tumor Microenvironment and Their Application in Early Diagnosis of Cancers

2020 ◽  
Vol 2020 ◽  
pp. 1-13 ◽  
Author(s):  
Rui Wei ◽  
Si Liu ◽  
Shutian Zhang ◽  
Li Min ◽  
Shengtao Zhu
Keyword(s):  
Tumor Microenvironment ◽  
Early Diagnosis ◽  
Immune Cells ◽  
Interstitial Fluid ◽  
Fluid Pressure ◽  
Early Diagnosis Of Cancer ◽  
Diagnosis Of Cancer ◽  
Chemical Factors ◽  
Physical And Chemical

Tumors are surrounded by complex environmental components, including blood and lymph vessels, fibroblasts, endothelial cells, immune cells, cytokines, extracellular vesicles, and extracellular matrix. All the stromal components together with the tumor cells form the tumor microenvironment (TME). In addition, extracellular physical and chemical factors, including extracellular pH, hypoxia, elevated interstitial fluid pressure, and fibrosis, are closely associated with tumor progression, metastasis, immunosuppression, and drug resistance. Cellular and extracellular components in TME contribute to nearly all procedures of carcinogenesis. By summarizing the recent work in this field, we make a comprehensive review on the role of cellular and extracellular components in the process of carcinogenesis and their potential application in early diagnosis of cancer. We hope that a systematic review of the diverse aspects of TME will help both research scientists and clinicians in this field.

scholarly journals Battling Chemoresistance in Cancer: Root Causes and Strategies to Uproot Them

2021 ◽  
Vol 22 (17) ◽  
pp. 9451
Author(s):  
Alisha Ramos ◽  
Samira Sadeghi ◽  
Hossein Tabatabaeian
Keyword(s):  
Tumor Microenvironment ◽  
Early Diagnosis ◽  
Combination Therapy ◽  
Cancer Treatment ◽  
Tumor Heterogeneity ◽  
Cancer Recurrence ◽  
Diverse Range ◽  
Early Diagnosis Of Cancer ◽  
Diagnosis Of Cancer ◽  
Underlying Mechanisms

With nearly 10 million deaths, cancer is the leading cause of mortality worldwide. Along with major key parameters that control cancer treatment management, such as diagnosis, resistance to the classical and new chemotherapeutic reagents continues to be a significant problem. Intrinsic or acquired chemoresistance leads to cancer recurrence in many cases that eventually causes failure in the successful treatment and death of cancer patients. Various determinants, including tumor heterogeneity and tumor microenvironment, could cause chemoresistance through a diverse range of mechanisms. In this review, we summarize the key determinants and the underlying mechanisms by which chemoresistance appears. We then describe which strategies have been implemented and studied to combat such a lethal phenomenon in the management of cancer treatment, with emphasis on the need to improve the early diagnosis of cancer complemented by combination therapy.

Sign in / Sign up

Export Citation Format

Share Document